A sampling of media coverage that profiles or mentions CCRM
McMaster Innovation Park Leads the Charge in Commercializing Discoveries through Advanced Biomanufacturing. Innovating Canada, June 15, 2021.
Canadians are polite, but we’re still recruiting your talent, America. TechCrunch, June 15, 2021.
Could this be the “holy grail for cell therapy”? Research 2 Reality, June 9, 2021.
Innovative surgery provides relief for patients with chronic pancreatitis. University Health Network, June 9, 2021.
CCRM enters regenerative medicine partnerships. Contract Pharma, June 1, 2021.
CCRM and Amgen partner to advance emerging medical innovations. Contract Pharma, May 3, 2021.
Galera claims positive update in pancreatic cancer but doesn’t report p-values; Amgen launches Canadian fund in tandem with CCRM. Endpoints News, April 29, 2021.
Being bionic: the future of regenerative medicine. Toronto Star, April 13, 2021.
Have you seen Hamilton? Site Selection Magazine, March 2021.
Canada’s biotech and life sciences sector needs an infusion of talent to scale. MaRS, March 30, 2021.
Toronto’s CCRM prepares for next wave of biomanufacturing demand. Toronto Star (print) and Health Insight (digital), March 27, 2021.
‘Industrializing the production of cells’: Another iPSC player joins the quest for off-the-shelf cell therapies. Endpoints News, February 10, 2021.
Biotech company founded by U of T researchers secures US$85 million in financing. University of Toronto News, February 10, 2021.
Vancouver biotech Notch Therapeutics raises US$85-million in venture funding. The Globe and Mail, February 10, 2021.
Allogene partner Notch snags $85M for renewable cell therapies. Fierce Biotech, February 10, 2021.
Pivotal Experiment Fund to accelerate Medicine by Design-funded research toward impact. Medicine by Design News, February 9, 2021.
Discovering the new life sciences district in Hamilton. Perspective, January 21, 2021.
Investors flock to Canadian device maker Sernova hoping to transform how diabetes is treated. The Globe and Mail, January 21, 2021.